The effect of myo-inositol and N-acetyl-L-cysteine on prepared sperms

The effect of myo-inositol and N-acetyl-L-cysteine on improving of the quantitative and qualitative indices of prepared sperms for using in Assisted Reproductive Technology (IVF/ICSI)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190204042618N2

Enrollment

Registered

2019-03-26

Start date

2018-04-19

Completion date

Unknown

Last updated

2019-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

male infertility. Male infertility

Interventions

Intervention 1: Intervention group: is incubated with myo-inositol drug(INOFOLIC Sachet, Parsian health) at a concentration of 2 mg / ml at 37 ° C for 20 minutes. Intervention 2: Intervention group:

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Infertility history for at least 12 months Infertility with male causes Non-use of minerals, multivitamins and any fertility enhancer drug during the last three months

Exclusion criteria

Exclusion criteria: Using alcoholic drinks or Unauthorized compounds and drugs(Opiate, Psychotropic drugs, Bodybuilding compounds, Antipsychotics, Sedative)

Design outcomes

Primary

Measure	Time frame
Sperm viability. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Trypan blue staining and contrast phase microscope.;Sperm morphology. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Contrast phase microscope, Sperm analyzer device.;Total sperm motility. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Contrast phase microscope, Sperm analyzer device.;SMI. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Sperm analyzer device.;PMSCa. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Contrast phase microscope, Sperm analyzer device.;PMSCb. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Contrast phase microscope, Sperm analyzer device.	—

Measure

Time frame

Sperm viability. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Trypan blue staining and contrast phase microscope.;Sperm morphology. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Contrast phase microscope, Sperm analyzer device.;Total sperm motility. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Contrast phase microscope, Sperm analyzer device.;SMI. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Sperm analyzer device.;PMSCa. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Contrast phase microscope, Sperm analyzer device.;PMSCb. Timepoint: Before the proximity to medication, at the end of the incubation period. Method of measurement: Contrast phase microscope, Sperm analyzer device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Nemati

Shahre-kord University of Medical Sciences

nemati.m2016@gmail.com+98 38 3224 8235

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026